Lexeo Therapeutics (LXEO) Change in Acquisitions & Divestments (2025 - 2026)
Lexeo Therapeutics (LXEO) posted Change in Acquisitions & Divestments of $27.5 million for Q1 2026, down 28.26% sequentially from $38.3 million in Q4 2025, and up 76.25% YoY from $15.6 million in Q1 2025.
Powered by 
Analysis
Lexeo Therapeutics (LXEO) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Change in Acquisitions & Divestments for 2 years, with the latest figure at $27.5 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments rose 76.25% year-over-year to $27.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.4 million (changed N/A YoY) and the FY2025 annual result came in at $105.5 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments declined to $27.5 million in Q1 2026 per LXEO's latest filing, from $38.3 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $38.3 million in Q4 2025 and troughed at $15.6 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 419.14 Mn | 419.14 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.24 Mn |
| Mar 31, 2026 | 27.50 Mn |
| Dec 31, 2025 | 38.33 Mn |
| Sep 30, 2025 | 35.30 Mn |
| Jun 30, 2025 | 16.30 Mn |
| Mar 31, 2025 | 15.60 Mn |